Evoxac Generic Launched; Agreements Reached on Orapred ODT Version, Risperdal

In recent generic drug developments, Ranbaxy Pharmaceuticals Inc. has launched an authorized version of Daiichi Sankyo’s Evoxac, and Mylan has reached a settlement agreement with Shionogi Inc. and CIMA Labs Inc. for a version of Orapred ODT.

Also, Breckenridge Pharmaceutical Inc. reached an agreement to market Ajanta Pharma’s generic version of Risperdal.

Ranbaxy Oct. 9 announced it has launched an authorized generic of Evoxac (cevimeline hydrochloride) 30 mg capsules in the United States under an agreement with Daiichi Sankyo. Evoxac is indicated for treating symptoms of dry mouth associated with Sjogren’s syndrome, an autoimmune disorder affecting the moisture-producing glands, the ...